Format

Send to

Choose Destination
Blood. 2017 Oct 12;130(15):1768-1771. doi: 10.1182/blood-2017-02-765032. Epub 2017 Aug 21.

Ruxolitinib for essential thrombocythemia refractory to or intolerant of hydroxyurea: long-term phase 2 study results.

Author information

1
Department of Leukemia, MD Anderson Cancer Center, University of Texas, Houston, TX.
2
Department of Medicine and Surgery, University of Insubria, Varese, Italy.
3
Hematology and Bone Marrow Transplant Unit, Azienda Ospedaliera Papa Giovanni XXII, Bergamo, Italy.
4
Dipartimento di Oncologia ed Emato-Oncologia, University of Milan, Milan, Italy.
5
Center for the Study of Myelofibrosis, Fondazione Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) Policlinico San Matteo Foundation, Pavia, Italy.
6
Department of Molecular Medicine, University of Pavia, Pavia, Italy.
7
Department of Hematology Oncology, IRCCS Policlinico San Matteo Foundation, Pavia, Italy.
8
Department of Oncology, Ospedale Santo Spirito, Casale Monferrato, Italy.
9
Center of Research and Innovation of Myeloproliferative Neoplasms, Azienda Ospedaliera Universitaria Careggi, Florence, Italy.
10
Department of Experimental and Clinical Medicine, Laboratorio Congiunto for Myeloproliferative Neoplasm, University of Florence, Florence, Italy.
11
Incyte Corporation, Wilmington, DE; and.
12
Clinical Research Foundation (FROM), Ospedale Papa Giovanni XXIII, Bergamo, Italy.
PMID:
28827411
PMCID:
PMC5639482
DOI:
10.1182/blood-2017-02-765032
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for HighWire Icon for PubMed Central
Loading ...
Support Center